Research programme: neurodegenerative disorder therapeutics - Noscira
Alternative Names: NP-17; NP-901; NPM-05 familyLatest Information Update: 07 Mar 2013
Price :
$50 *
At a glance
- Originator Neuropharma
- Developer Noscira
- Class
- Mechanism of Action Amyloid precursor protein secretase inhibitors; Amyloid precursor protein secretase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Neurological disorders